Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.74 |
| ▸ | IKZF3 | Q9UKT9 | 17/20 | 0.74 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.74 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.74 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.74 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.74 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25662571 | 0.85 | CRBN (0.55) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL25970648 | 0.85 | CRBN (0.55) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| Mezigdomide SCHEMBL29370160 | 0.85 | CRBN (1.00) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| Mezigdomide SCHEMBL20608546 | 0.85 | CRBN (1.00) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| Mezigdomide SCHEMBL20608563 | 0.85 | CRBN (1.00) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| Mezigdomide SCHEMBL29444146 | 0.85 | CRBN (1.00) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| Mezigdomide SCHEMBL20608547 | 0.85 | CRBN (1.00) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| Mezigdomide SCHEMBL29520046 | 0.85 | CRBN (1.00) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL25664216 | 0.84 | CRBN (0.53) | CRBNIKZF3DDB1ADRA1DADRA1A | |
| SCHEMBL25662606 | 0.83 | CRBN (0.52) | CRBNIKZF3DDB1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11185543-B2 | Antiproliferative compounds and methods of use thereof | CELGENE CORPORATION (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200253964-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | CELGENE CORPORATION | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11185543-B2 | Antiproliferative compounds and methods of use thereof | MCL1, NPM1, NFATC1 | CRBN 21/4885IKZF3 498/4885DDB1 286/4885 |
| US-20200253964-A1 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | MCL1, NPM1, NFATC1 | CRBN 21/4885IKZF3 498/4885DDB1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.